BioGraphene Signs Collaborative Research Agreement with Samsung Medical Center for the Efficacy Study of Graphene Quantum Dots in Alzheimer’s Disease

BioGraphene Inc. announced that the company and Samsung Medical Center entered into a Collaborative Research Agreement for the efficacy study of Graphene Quantum Dots (GQDs) in Alzheimer’s Disease.

Dr. Duk L Na, a professor at the Department of Neurology at SungKyunKwan University School of Medicine and Samsung Medical Center will lead the research and validate GQD’s efficacy in Alzheimer’s Disease using in vitro/in vivo model.

Alzheimer’s Disease is a neurologic disorder that causes brain shrinkage, neuronal loss and subsequent dementia. It is associated with the abnormal accumulation of toxic amyloid beta oligomers and plaques as well as tau proteins in the brain. It is the most prevalent neurodegenerative disease with varying progression. All currently approved treatments for Alzheimer’s Disease are “symptomatic” agents that aim to improve cognitive and behavioral symptoms without altering the underlying course of the disease.

BioGraphene’s biocompatible GQDs already showed the efficacy in Parkinson’s disease. Based on mode of action of GQDs discovered so far, Alzheimer’s Disease may be the potential target for GQDs.